CA2972817C - Utilisation de prg4 comment agent anti-inflammatoire - Google Patents

Utilisation de prg4 comment agent anti-inflammatoire

Info

Publication number
CA2972817C
CA2972817C CA2972817A CA2972817A CA2972817C CA 2972817 C CA2972817 C CA 2972817C CA 2972817 A CA2972817 A CA 2972817A CA 2972817 A CA2972817 A CA 2972817A CA 2972817 C CA2972817 C CA 2972817C
Authority
CA
Canada
Prior art keywords
prg4
cell
rhprg4
lubricin
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2972817A
Other languages
English (en)
Other versions
CA2972817A1 (fr
Inventor
Gregory D. Jay
Benjamin D. Sullivan
Tannin Avery Schmidt
Khaled Elsaid
Edward R. Truitt
Roman Krawetz
Joanna Szmydynger-Chodobska
Adam Chodobski
Jawed Fareed
Original Assignee
Rhode Island Hospital
Lubris LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhode Island Hospital, Lubris LLC filed Critical Rhode Island Hospital
Priority claimed from PCT/US2016/014952 external-priority patent/WO2016123123A1/fr
Publication of CA2972817A1 publication Critical patent/CA2972817A1/fr
Application granted granted Critical
Publication of CA2972817C publication Critical patent/CA2972817C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne des procédés d'utilisation de la glycoprotéine PRG4, également connue sous le nom de lubricine, pour réduire, inhiber, ou réguler négativement les voies pro-inflammatoires chez des patients présentant un risque ou souffrant de réponse inflammatoire ou de symptôme d'allergie par le biais de l'antagonisation de CD44, de régulation de la production de cytokines pro-inflammatoires, d'inhibition de la translocation de NF-?? et/ou de facilitation de l'élimination de débris ou allergènes cellulaires ou matriciels induisant l'inflammation.
CA2972817A 2015-01-26 2016-01-26 Utilisation de prg4 comment agent anti-inflammatoire Active CA2972817C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562107799P 2015-01-26 2015-01-26
US62/107,799 2015-01-26
US201562273059P 2015-12-30 2015-12-30
US62/273,059 2015-12-30
PCT/US2016/014952 WO2016123123A1 (fr) 2015-01-26 2016-01-26 Utilisation de prg4 comment agent anti-inflammatoire

Publications (2)

Publication Number Publication Date
CA2972817A1 CA2972817A1 (fr) 2016-08-04
CA2972817C true CA2972817C (fr) 2025-09-09

Family

ID=

Similar Documents

Publication Publication Date Title
US11717557B2 (en) Use of PRG4 as an anti-inflammatory agent
US20250195608A1 (en) Therapeutic Compositions for the Treatment of Dry Eye Disease
US9872901B2 (en) Therapeutic compositions for treatment of ocular inflammatory disorders
ES2846789T3 (es) Composiciones que contienen complejos HC-HA/PTX3 y métodos de uso de los mismos
JP6004494B2 (ja) デュピュイトラン病の治療
US20130116186A1 (en) Lubricin injections to maintain cartilage health
EP3065765A1 (fr) Utilisation de dimères d'il-22 dans la fabrication de médicaments pour le traitement de la pancréatite
US20180161393A1 (en) Prg4 for treating gout and its symptoms
CA2972817C (fr) Utilisation de prg4 comment agent anti-inflammatoire
HK40036871A (en) Use of prg4 as an anti-inflammatory agent
Singh et al. Osteoarthritis: Insights into pathogenesis and futuristic treatment strategies
HK1247834B (en) Use of prg4 as an anti-inflammatory agent
AU2017205185B2 (en) Therapeutics for ocular immunoinflammatory diseases
ES2892048T3 (es) Composiciones terapéuticas para el tratamiento de trastornos inflamatorios oculares